TD has acquired Cowen Inc. Please bookmark TD Securities for further updates.

$633 Million

Allogene Therapeutics

Follow-on Offering

Bookrunner, June 2020

Allogene Therapeutics

Allogene Therapeutics, Inc. is a clinical-stage immuno-oncology company pioneering the development and commercialization of genetically engineered allogeneic T cell therapies for cancer. In collaboration with Servier, Allogene is developing UCART19, ALLO-501 and ALLO-501A, which are CAR T cell product candidates targeting CD19.